Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CHGCF
Stock Latest News
Company Announcements
Chugai Pharmaceutical’s Promising Phase III Study on Ulcerative Colitis Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical Advances Satralizumab Trial for Autoimmune Encephalitis
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s Satralizumab Study: A Potential Game-Changer for MOGAD Treatment?
4d ago
CHGCF
Premium
Company Announcements
Chugai’s Phase III Study on Divarasib: A Potential Game-Changer in Lung Cancer Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s Promising Phase III Study on Crohn’s Disease Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s Promising Phase III Study on Crohn’s Disease Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai’s Promising Lung Cancer Study: A Potential Game-Changer?
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s AUBE00 Study: A Potential Game-Changer in Cancer Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s New Phase I Trial: A Potential Game-Changer in Lung Cancer Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai’s RAINBOW-LTE Trial: A Promising Step in Immunological Disease Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai’s RAINBOW Trial: A New Hope in Immunological Disease Treatment
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical’s Promising Phase I Study on ROSE12 for Solid Tumors
4d ago
CHGCF
Premium
Company Announcements
Chugai Pharmaceutical Acquires Renalys Pharma to Expand IgA Nephropathy Treatment
7d ago
Premium
Company Announcements
Chugai Pharmaceutical Reports Strong Q3 Results and Announces Special Dividend
7d ago
Premium
Company Announcements
Chugai Pharmaceutical’s Role in Roche’s Q3 2025 Sales Announcement
9d ago
Premium
Pre-Earnings
CHGCF Earnings this Week: How Will it Perform?
9d ago
Premium
Company Announcements
Chugai Partners with Rani Therapeutics for Innovative Oral Biologics
12d ago
Premium
Company Announcements
Eli Lilly’s Orforglipron Shows Superior Results in Diabetes Trial
1M ago
Premium
Company Announcements
Chugai Announces Positive Phase 3 Results for Eli Lilly’s Orforglipron
2M ago
Premium
Company Announcements
Chugai Highlights Eli Lilly’s Positive Phase 3 Results for Orforglipron
3M ago
Premium
Company Announcements
Chugai Pharmaceutical Reports Strong H1 2025 Performance
3M ago
Premium
Company Announcements
Chugai Pharmaceutical Co’s Earnings Call: Balancing Growth and Challenges
3M ago
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.